ValuEngine upgraded shares of Zynex Inc. common stock (OTCMKTS:ZYXI) from a sell rating to a hold rating in a research report released on Saturday.

Separately, Zacks Investment Research downgraded Zynex Inc. common stock from a hold rating to a sell rating in a research report on Friday, August 10th.

OTCMKTS:ZYXI opened at $3.12 on Friday. The firm has a market cap of $96.38 million, a P/E ratio of 14.18 and a beta of 1.01. Zynex Inc. common stock has a 52-week low of $1.00 and a 52-week high of $5.50.

Zynex Inc. common stock (OTCMKTS:ZYXI) last posted its quarterly earnings data on Thursday, August 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.01. The company had revenue of $7.57 million during the quarter, compared to analyst estimates of $7.75 million. Zynex Inc. common stock had a return on equity of 205.15% and a net margin of 33.49%. equities analysts expect that Zynex Inc. common stock will post 0.28 EPS for the current fiscal year.

Zynex Inc. common stock Company Profile

Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.

Recommended Story: What are CEFs?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Zynex Inc. common stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex Inc. common stock and related companies with MarketBeat.com's FREE daily email newsletter.